The CNPEM signed a cooperation agreement in 2021 with three startups in the area of biotechnology applied to healthcare: Next Innovative Therapeutics (Nintx), focusing on research involving natural products from Brazil’s biodiversity to develop new multi-target therapies to treat infectious diseases; 3D Biotechnology (3DBS), a company that works in regenerative medicine, to develop equipment and applications that involve biomimetic tissues and functional in vitro models; and Advagen Biotech, which develops kits and methodologies to diagnose diseases such as Zika and the novel coronavirus.

In recent years the CNPEM has strengthened its ties with startups in various collaborations with domestic companies, with training and updates related to technology as well as management of innovation and business. Two spin-offs have already been created with technologies licensed from the Center, and various startups have been developed after involvement with Sirius.

These startups are strategic companies for the National System for Science, Technology, and Innovation since they are responsible for creating innovations with major potential in business involving risks that mature companies hesitate to take on, catalyzing the economy and technological development in the country.